DJI136 CAR-T Therapy for Small Cell Lung Cancer

This trial aims to determine the optimal dose and assess the safety and effectiveness of a new treatment called DJI136 CAR-T therapy for individuals with extensive-stage small cell lung cancer (ES-SCLC). The study consists of two parts: the first part identifies the appropriate dose, while the second part evaluates the treatment's effectiveness at that dose. It targets those who have previously undergone chemotherapy with a platinum-based medicine and a PD-L1 inhibitor but require additional options. Participants must have a confirmed diagnosis of small cell lung cancer and at least one measurable tumor. As a Phase 1, Phase 2 trial, this research seeks to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering a chance to be among the first to benefit from this innovative therapy.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor to get specific guidance based on your situation.

Early lab studies have shown that DJI136, a type of CAR-T therapy, is safe and effective in small cell lung cancer models. This treatment targets a protein called DLL3, found on cancer cells. Although researchers are still testing DJI136 in people, similar treatments have shown side effects like fever, tiredness, and low blood cell counts, with serious side effects being less common. These studies aim to find the safest dose and identify any side effects. Ongoing research will help determine how well patients can tolerate DJI136.¹²³⁴⁵

Researchers are excited about DJI136 CAR-T Therapy for small cell lung cancer because it represents a new approach in cancer treatment. Unlike standard chemotherapy and radiation, which attack cancer cells broadly, DJI136 uses a patient's own genetically modified T-cells to specifically target and destroy cancer cells. This personalized treatment could potentially lead to fewer side effects and improved efficacy. By harnessing the body's immune system, DJI136 offers a promising alternative to traditional therapies, which often come with significant side effects and varied effectiveness.

Research has shown that DJI136, a type of CAR-T cell therapy targeting DLL3, may help treat extensive-stage small cell lung cancer (ES-SCLC). In studies with patients whose cancer returned or didn't respond to other treatments, DJI136 shrank or eliminated cancer in about 29 out of 100 people. Additionally, nearly 79 out of 100 patients experienced control over their cancer's growth. This trial will evaluate DJI136 in two phases: Phase I will focus on dose escalation, and Phase II will treat participants at the recommended dose(s) identified in Phase I. These early findings suggest that DJI136 could effectively manage ES-SCLC, but more research is needed to fully understand its potential.¹²³⁴⁶